Results 31 to 40 of about 38,166 (233)

Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. [PDF]

Lancet Glob Health, 2022
Bashorun AO, Badjie Hydara M, Adigweme I, Umesi A, Danso B, Johnson N, Sambou NA, Fofana S, Kanu FJ, Jeyaseelan V, Verma H, Weldon WC, Oberste MS, Sutter RW, Jeffries D, Wathuo M, Mach O, Clarke E.   +17 more
europepmc   +2 more sources

Immunogenicity and safety of co-administration with the Sabin-strain-based inactivated poliovirus vaccine (vero cell) and the diphtheria-tetanus-acellular pertussis vaccine in eligible children in China: a randomized, controlled, multicenter, non-inferiority trial. [PDF]

Front Immunol
Liu X, Han S, Chen X, Sun L, Wang R, Shi X, Guo Y, Wang H, Chen H, Chang S, Xu X, Zhang C, Wang Y, Zhang D, Hu W, Zhang S.   +15 more
europepmc   +3 more sources

Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study. [PDF]

Vaccine, 2023
Erdem R, De Coster I, Withanage K, Mercer LD, Marchant A, Taton M, Cools N, Lion E, Cassels F, Higgins D, Ivinson K, Locke E, Mahmood K, Wright PF, Gast C, White JA, Ackerman ME, Konopka-Anstadt JL, Mainou BA, Van Damme P.   +19 more
europepmc   +2 more sources

Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. [PDF]

Vaccine
Thompson KM, Kalkowska DA, Kidd SE, Burns CC, Badizadegan K.   +4 more
europepmc   +2 more sources

Quantitative Analysis of the Instant and Persistent Inhibition Effects of Maternal Poliovirus Antibodies on the Immune Response in a Phase IV Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine. [PDF]

Vaccines (Basel)
Yin Q, Zheng Y, Ying Z, Li J, Jiang Y, Bao W, Dou Y, Pu Y, Lei J, Yang H, Jiang R, Deng Y, Zhao Z, Pu J, Yang J, Li Y, Xu M, Cai W, Che Y, Shi L.   +19 more
europepmc   +3 more sources

Inactivated Poliovirus Vaccine Booster Reduces the Likelihood of COVID-19 Outcomes in Individuals Primed with Oral Poliovirus Vaccination. [PDF]

Vaccines (Basel)
Comunale BA, Larson RJ, Hsu YJ, Jackson-Ward E, Azodoh C, Singh A, Engineer LD.   +6 more
europepmc   +3 more sources

Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial

Vaccine, 2022
Jessica W. Crothers, E. Ross Colgate, Kelly J. Cowan, Dorothy M. Dickson, Mary C. Walsh, M. Carmolli, Peter F. Wright, E. Norton, B. Kirkpatrick   +8 more
semanticscholar   +2 more sources

Change from oral poliovirus vaccine to inactivated poliovirus vaccine [PDF]

The Lancet, 2002
Alfonso Mele, Tom Jefferson, Elisabetta Franco, Stefania Salmaso   +3 more
openaire   +2 more sources

Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel? [PDF]

J Infect Dis, 2019
Sutter RW, Cochi SL.
europepmc   +2 more sources

Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.

Lancet Infect Dis, 2021
Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, Oberste MS, Weldon WC, Modlin J, Clemens R, Costa Clemens SA, Jimeno J, Rüttimann R.   +10 more
europepmc   +2 more sources